Research programme: botulinum toxin A therapeutics - Revance TherapeuticsAlternative Names: RT401
Latest Information Update: 16 Jul 2016
At a glance
- Originator Revance Therapeutics
- Class Bacterial proteins; Bacterial toxins; Botulinum toxins
- Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Rhinitis